Home » Topics » Disease categories and therapies » Urology

Urology
RSS

VPA-985 characterized as potent, selective, orally active V2 antagonist

Nov. 13, 1998

No Comments

Sepracor announces results of phase II pilot trial for (S)-oxybutynin

Nov. 13, 1998

No Comments

RenaGel available this month in the U.S.

Nov. 11, 1998

No Comments

Alza focuses on urology products; licenses Urispas

Nov. 4, 1998

No Comments

U.S. grants first approval for GelTex's novel phosphate-binding polymer therapeutic

Nov. 3, 1998

No Comments

Synthelabo team presents new agents for incontinence

Nov. 3, 1998

No Comments

Basis of beneficial effects of cactus flower in BPH

Oct. 30, 1998

No Comments

Milkhaus successfully completes phase II trial of BPH therapeutic

Oct. 21, 1998

No Comments

Celsion ready to begin BPH treatment studies

Oct. 20, 1998

No Comments

Boston Scientific to copromote Targis System for BPH

Oct. 16, 1998

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Urology
RSS

VPA-985 characterized as potent, selective, orally active V2 antagonist

Sepracor announces results of phase II pilot trial for (S)-oxybutynin

RenaGel available this month in the U.S.

Alza focuses on urology products; licenses Urispas

U.S. grants first approval for GelTex's novel phosphate-binding polymer therapeutic

Synthelabo team presents new agents for incontinence

Basis of beneficial effects of cactus flower in BPH

Milkhaus successfully completes phase II trial of BPH therapeutic

Celsion ready to begin BPH treatment studies

Boston Scientific to copromote Targis System for BPH

Today's news in brief

Today's news in brief

STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space

GLP-1 receptor agonists continue their global victory tour

AI drives financings, approvals for APAC med-tech in 2024

Urology RSS

Urology
RSS